vs

Side-by-side financial comparison of Caesarstone Ltd. (CSTE) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Caesarstone Ltd. is the larger business by last-quarter revenue ($94.4M vs $74.7M, roughly 1.3× Health Catalyst, Inc.). Caesarstone Ltd. runs the higher net margin — -93.1% vs -121.9%, a 28.8% gap on every dollar of revenue. Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-47.1M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -57.8%).

Caesarstone Ltd., is a publicly traded company that engages in the production and marketing of quartz, porcelain, mineral and advanced fusion surfaces used for kitchen countertops, vanity tops, flooring, wall cladding and general interior design. The company was founded in 1987 and is traded on the NASDAQ in New York (CSTE). Headquarters are located in Kibbutz Sdot Yam in Israel. Production facilities are in Israel and India with third party manufactured product sourced from factories in the ...

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

CSTE vs HCAT — Head-to-Head

Bigger by revenue
CSTE
CSTE
1.3× larger
CSTE
$94.4M
$74.7M
HCAT
Higher net margin
CSTE
CSTE
28.8% more per $
CSTE
-93.1%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$56.7M more FCF
HCAT
$9.6M
$-47.1M
CSTE
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-57.8%
CSTE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CSTE
CSTE
HCAT
HCAT
Revenue
$94.4M
$74.7M
Net Profit
$-87.9M
$-91.0M
Gross Margin
15.5%
Operating Margin
-87.2%
-115.3%
Net Margin
-93.1%
-121.9%
Revenue YoY
-6.2%
Net Profit YoY
-340.3%
EPS (diluted)
$-2.55
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSTE
CSTE
HCAT
HCAT
Q4 25
$94.4M
$74.7M
Q3 25
$345.4M
$76.3M
Q2 25
$237.7M
$80.7M
Q1 25
$79.4M
Q4 24
$79.6M
Q3 24
$436.7M
$76.4M
Q2 24
$294.3M
$75.9M
Q1 24
$150.6M
$74.7M
Net Profit
CSTE
CSTE
HCAT
HCAT
Q4 25
$-87.9M
$-91.0M
Q3 25
$-18.5M
$-22.2M
Q2 25
$-14.3M
$-41.0M
Q1 25
$-23.7M
Q4 24
$-20.7M
Q3 24
$-57.4M
$-14.7M
Q2 24
$-56.6M
$-13.5M
Q1 24
$-3.9M
$-20.6M
Gross Margin
CSTE
CSTE
HCAT
HCAT
Q4 25
15.5%
Q3 25
22.5%
52.6%
Q2 25
23.7%
Q1 25
Q4 24
Q3 24
15.7%
47.5%
Q2 24
14.1%
Q1 24
19.7%
Operating Margin
CSTE
CSTE
HCAT
HCAT
Q4 25
-87.2%
-115.3%
Q3 25
-5.5%
-22.9%
Q2 25
-6.2%
-46.0%
Q1 25
-25.4%
Q4 24
-22.0%
Q3 24
-12.6%
-17.9%
Q2 24
-18.0%
-20.8%
Q1 24
-3.9%
-30.5%
Net Margin
CSTE
CSTE
HCAT
HCAT
Q4 25
-93.1%
-121.9%
Q3 25
-5.4%
-29.1%
Q2 25
-6.0%
-50.8%
Q1 25
-29.9%
Q4 24
-26.0%
Q3 24
-13.1%
-19.3%
Q2 24
-19.2%
-17.8%
Q1 24
-2.6%
-27.6%
EPS (diluted)
CSTE
CSTE
HCAT
HCAT
Q4 25
$-2.55
$-1.29
Q3 25
$-0.54
$-0.32
Q2 25
$-0.41
$-0.59
Q1 25
$-0.35
Q4 24
$-0.33
Q3 24
$-1.67
$-0.24
Q2 24
$-1.64
$-0.23
Q1 24
$-0.11
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSTE
CSTE
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$58.4M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$139.2M
$245.8M
Total Assets
$398.4M
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSTE
CSTE
HCAT
HCAT
Q4 25
$58.4M
$95.7M
Q3 25
$91.5M
Q2 25
$97.3M
Q1 25
$342.0M
Q4 24
$392.0M
Q3 24
$387.3M
Q2 24
$308.3M
Q1 24
$327.8M
Total Debt
CSTE
CSTE
HCAT
HCAT
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
$-12.6M
Stockholders' Equity
CSTE
CSTE
HCAT
HCAT
Q4 25
$139.2M
$245.8M
Q3 25
$271.6M
$331.9M
Q2 25
$271.6M
$347.5M
Q1 25
$376.8M
Q4 24
$365.2M
Q3 24
$315.1M
$355.0M
Q2 24
$315.1M
$357.0M
Q1 24
$315.1M
$357.2M
Total Assets
CSTE
CSTE
HCAT
HCAT
Q4 25
$398.4M
$502.6M
Q3 25
$549.0M
$587.1M
Q2 25
$549.0M
$616.2M
Q1 25
$891.5M
Q4 24
$858.9M
Q3 24
$579.9M
$813.0M
Q2 24
$579.9M
$691.7M
Q1 24
$579.9M
$695.1M
Debt / Equity
CSTE
CSTE
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24
-0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSTE
CSTE
HCAT
HCAT
Operating Cash FlowLast quarter
$-38.0M
$9.9M
Free Cash FlowOCF − Capex
$-47.1M
$9.6M
FCF MarginFCF / Revenue
-49.8%
12.9%
Capex IntensityCapex / Revenue
9.6%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$38.6M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSTE
CSTE
HCAT
HCAT
Q4 25
$-38.0M
$9.9M
Q3 25
$35.0M
$-464.0K
Q2 25
$18.7M
$-9.0M
Q1 25
$280.0K
Q4 24
$-3.5M
Q3 24
$53.3M
$6.2M
Q2 24
$25.1M
$1.6M
Q1 24
$7.9M
$10.3M
Free Cash Flow
CSTE
CSTE
HCAT
HCAT
Q4 25
$-47.1M
$9.6M
Q3 25
$26.7M
$-719.0K
Q2 25
$14.3M
$-9.2M
Q1 25
$-390.0K
Q4 24
$-3.9M
Q3 24
$44.6M
$5.5M
Q2 24
$20.7M
$1.3M
Q1 24
$5.0M
$10.1M
FCF Margin
CSTE
CSTE
HCAT
HCAT
Q4 25
-49.8%
12.9%
Q3 25
7.7%
-0.9%
Q2 25
6.0%
-11.4%
Q1 25
-0.5%
Q4 24
-4.9%
Q3 24
10.2%
7.2%
Q2 24
7.0%
1.7%
Q1 24
3.3%
13.5%
Capex Intensity
CSTE
CSTE
HCAT
HCAT
Q4 25
9.6%
0.4%
Q3 25
2.4%
0.3%
Q2 25
1.8%
0.3%
Q1 25
0.8%
Q4 24
0.5%
Q3 24
2.0%
0.9%
Q2 24
1.5%
0.4%
Q1 24
1.9%
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CSTE
CSTE

America's$53.0M56%
USA$41.4M44%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons